Introduction {#s1}
============

Because myocardial infarction usually results from occlusive thrombosis of atherosclerotic plaque, it has been proposed that circulating levels of markers that reflect activated coagulation and fibrinolysis may be associated with coronary heart disease (CHD) risk [@pone.0055175-Borissoff1], [@pone.0055175-Lowe1]. Three such markers are tissue plasminogen activator (t-PA) antigen, D-dimer and von Willebrand factor (VWF). t-PA is the principal regulator of endogenous fibrinolysis catalyzing the conversion of plasminogen to plasmin [@pone.0055175-Plow1]. In circulation, however, most of t-PA is bound to its inhibitor PAI-1 (plasminogen activator inhibitor type 1) and this complex can be measured as t-PA antigen [@pone.0055175-Nordenhem1], with high levels indicating biologically inactive t-PA and hence tendency to clot formation. D-dimer is a marker of activated coagulation and fibrinolysis and its levels reflect active fibrin mesh formation and degradation [@pone.0055175-Lip1]. VWF is an important cofactor in platelet adhesion and platelet aggregation, key steps in primary hemostasis [@pone.0055175-Vischer1]. Previous studies have suggested significant and moderately strong associations of these markers with CHD risk in essentially general and secondary prevention populations [@pone.0055175-Danesh1]--[@pone.0055175-Lowe2], with perhaps stronger associations for myocardial infarction or fatal CHD than for incident stable angina, consistent with potential roles for activation of coagulation and fibrinolysis in coronary artery thrombosis, rather than atherogenesis [@pone.0055175-Wannamethee1]. To date, however, the available evidence for t-PA antigen and D-dimer has been limited to studies with only a few hundred CHD cases; insufficient to examine potentially important aspects such as the shape of dose-response relationships and the magnitude of these associations both overall and in clinically relevant subgroups with appropriate power.

To help clarify these uncertainties, we report new data on t-PA antigen and D-dimer involving 5541 participants in a prospective case-control comparison nested within the population-based Reykjavik Study of almost 19,000 middle aged Icelandic men and women monitored for a mean duration of about 20 years (results for VWF are presented here for comparison and have been reported previously [@pone.0055175-Danesh2], [@pone.0055175-Danesh3]). Context for our new data was provided by conducting a systematic review and updated meta-analyses of published reports on t-PA antigen, D-dimer and VWF and incident CHD.

Methods {#s2}
=======

Study Population {#s2a}
----------------

The Reykjavik Study, initiated in 1967, has been described in detail elsewhere [@pone.0055175-Jnsdttir1]. All men born between 1907 and 1934 and all women born between 1908 and 1935 who were registered to live in Reykjavik, Iceland, or its adjacent communities on December 1^st^ 1966 were invited to participate in the study (**[Figure S1](#pone.0055175.s001){ref-type="supplementary-material"}**). During five stages of recruitment between 1967 and 1991, a total of 9139 men and 9773 women were enrolled (response rate = 72%). Nurses administered questionnaires, made physical measurements, recorded electrocardiograms and collected fasting venous blood samples for preparation of aliquots of serum, which were stored at --20°C for subsequent analysis. All participants were monitored by central registries for occurrence of major coronary events (based on MONICA criteria [@pone.0055175-TunstallPedoe1]) or cause-specific mortality (based on a death certificate with International Classification of Diseases), with a loss to follow-up of only about 0.6% to date. Cause-specific mortality was coded using ICD-9 and ICD-10. CHD deaths were pre-defined as those allocated ICD-9 codes 410--414 and ICD-10 codes I20--I25. We selected 1925 participants who suffered a first-ever non-fatal MI or coronary death between study entry and the censoring date (median duration of follow-up, 19.4 years) and without evidence of cardiovascular disease at baseline, in whom baseline serum was available for measurement of t-PA antigen, D-dimer and VWF. We selected a random subset of 3616 controls from among the participants who had survived to the end of the study period without developing CHD, frequency matched to cases by recruitment year, age (in five-year age bands) and sex. Baseline characteristics of selected controls were broadly comparable to those of the overall Reykjavik cohort (**[Table S1](#pone.0055175.s011){ref-type="supplementary-material"}**). The National Bioethics Committee and the Data Protection Authority of Iceland approved the study protocol. All participants gave informed written consent and the study complies with the Declaration of Helsinki.

Laboratory Methods {#s2b}
------------------

All measurements were made in serum samples, by laboratory staff unaware of participants' disease status. Enzyme immunoassays were used to determine levels of t-PA antigen (Biopool AB, Umea, Sweden), D-dimer (Hyphen, Paris, France) and VWF (in-house assay using reagents from DAKO, Copenhagen, Denmark). All intra- and inter-assay coefficients of variation were \<5%. Lipid and other biochemical measurements have been described previously [@pone.0055175-Danesh2]--[@pone.0055175-Jnsdttir1].

Statistical Analyses {#s2c}
--------------------

All analyses were restricted to participants with complete information on t-PA antigen, D-dimer and VWF. Normal distributions were achieved by taking natural logarithms (log~e~) of positively skewed variables. Odds ratios (ORs) per 1 standard deviation (SD) higher log~e~ t-PA antigen, log~e~ D-dimer and log~e~ VWF were calculated using unconditional logistic regression. The SDs for baseline levels of log~e~ t-PA antigen, log~e~ D-dimer and log~e~ VWF were 0.5, 1.0 and 0.4, corresponding to 1.6-, 2.7- and 1.5-fold differences on the original scale (ie, *e* ^0.5^, *e* ^1.0^ and *e* ^0.4^). To assess the independence of associations from conventional cardiovascular risk factors, ORs were adjusted progressively for age, sex, period of recruitment, smoking, body mass index, history of diabetes, systolic blood pressure, total cholesterol and log~e~ triglycerides. To assess shapes of associations, adjusted ORs were calculated across fifths of the baseline levels of t-PA antigen, D-dimer and VWF in controls and 95% confidence intervals (CIs) were estimated from the floated variances [@pone.0055175-Plummer1]. Subgroup analyses were pre-specified and investigated by formal tests of interaction. Linear regression was used to assess the association between t-PA antigen, D-dimer and VWF and baseline characteristics among controls. To minimize biases resulting from measurement error, we corrected for regression dilution in supplementary analyses. Regression dilution ratios (RDR), as a measure of long-term within-person variability, were calculated for each characteristic by regressing its serial measurements on baseline levels, adjusted for potential confounding factors [@pone.0055175-FibrinogenStudies1]. Based on these regression models, predictions of long-term average levels ("usual levels") of t-PA antigen, D-dimer and VWF for each participant were then used to estimate ORs corrected for within-person variability, as described previously [@pone.0055175-FibrinogenStudies1]. An updated meta-analysis was conducted of prospective studies, published before October 19^th^ 2012, with more than one year of follow-up in essentially general populations (ie, in cohorts not selected on the basis of pre-existing disease) ([**Figure 1**](#pone-0055175-g001){ref-type="fig"} **, [Methods S1](#pone.0055175.s014){ref-type="supplementary-material"}, [Figure S2](#pone.0055175.s002){ref-type="supplementary-material"}** and **[Table S2](#pone.0055175.s012){ref-type="supplementary-material"}**). To enable comparability between study reports, risk estimates and 95% CIs were transformed to a common scale (ie, per 1 SD higher levels of the population's baseline distribution of the respective marker) using methods previously described [@pone.0055175-Danesh2]. Study-specific risk estimates were pooled by random-effects meta-analyses. Odds and hazard ratios were assumed to approximate the same underlying measure of relative risk (RR). Consistency of findings across studies was assessed with standard *χ* ^2^ tests and the *I* ^2^ statistic [@pone.0055175-Higgins1]. Subgroup analyses were conducted using meta-regression across pre-specified study-level characteristics [@pone.0055175-Thompson1]. Evidence of publication bias was assessed with funnel plots, Egger's test [@pone.0055175-Egger1], and by comparing pooled results from studies involving at least 500 CHD cases with pooled results from smaller studies. All analyses were performed using Stata release 12.1 (StataCorp, College Station, Texas). Statistical tests were two-sided and used a significance level of *P*\<0.05.

![Study flow diagram of the updated meta-analyses.\
The figure was designed based on the 2009 PRISMA flow diagram template (available from <http://www.prisma-statement.org/statement.htm>).](pone.0055175.g001){#pone-0055175-g001}

Results {#s3}
=======

Baseline Characteristics and Cross-sectional Associations in the Reykjavik Study {#s3a}
--------------------------------------------------------------------------------

In addition to significant differences between cases and controls with respect to conventional risk factors in the Reykjavik Study, baseline concentrations of t-PA antigen and VWF were significantly higher in cases than in controls, while there were no significant differences in D-dimer concentration ([**Table 1**](#pone-0055175-t001){ref-type="table"}). Baseline levels of t-PA antigen, D-dimer and VWF were significantly correlated with each other, with t-PA antigen and D-dimer being inversely associated ([**Table 1**](#pone-0055175-t001){ref-type="table"} and **[Figures S3](#pone.0055175.s003){ref-type="supplementary-material"}** to **[S5](#pone.0055175.s005){ref-type="supplementary-material"}**). All three markers were positively associated with age, smoking and inflammatory markers. Male sex and baseline measurements of body mass index, blood pressure, total cholesterol, log~e~ triglycerides, hematocrit, hemoglobin and log~e~ erythrocyte sedimentation rate showed positive correlations with levels of t-PA antigen, but negative correlations with D-dimer. In comparison, age- and sex-adjusted cross-sectional correlations of VWF were generally weaker.

10.1371/journal.pone.0055175.t001

###### Baseline characteristics of coronary heart disease cases and matched controls in the Reykjavik Study, and correlations with t-PA antigen, D-dimer and VWF.

![](pone.0055175.t001){#pone-0055175-t001-1}

  Variable                                                     Summary of baseline values                      Cross-sectional correlation with hemostatic markers                                                                      
  ----------------------------------------------------------- ---------------------------- ------------------ ----------------------------------------------------- ------------------ ---------- ----------------- ------------------- ---------------
  **Questionnaire-based**                                                                                                                                                                                                               
  Age, years                                                              1925                 54.2 (8.7)                             3616                              55.2 (9.0)      Matched     8% (6 to 11)      24% (19 to 29)     9% (7 to 11)
  Male sex                                                                1925                 1347 (70%)                             3616                              2441 (68%)      Matched    23% (19 to 27)    −28% (−33 to −23)    3% (1 to 6)
  Current smoker                                                          1925                 1153 (60%)                             3616                              1751 (48%)      \<0.0001     4% (1 to 7)       7% (0 to 14)       5% (3 to 8)
  History of diabetes                                                     1925                  51 (3%)                               3616                               58 (2%)         0.011     −3% (−15 to 10)   −10% (−30 to 15)    6% (−5 to 17)
  **Physical measurements**                                                                                                                                                                                                             
  Body mass index, kg/m^2^                                                1925                 26.0 (3.9)                             3616                              25.4 (3.7)      \<0.0001   20% (18 to 21)    −16% (−18 to −13)    1% (0 to 2)
  Systolic blood pressure, mmHg                                           1925                146.7 (21.7)                            3616                             141.9 (20.1)     \<0.0001    11% (9 to 13)     −6% (−9 to −3)      1% (0 to 3)
  Diastolic blood pressure, mmHg                                          1924                90.2 (11.0)                             3615                             87.5 (10.8)      \<0.0001   13% (12 to 15)     −8% (−11 to −5)    1% (−1 to 2)
  **Lipid markers**                                                                                                                                                                                                                     
  Total cholesterol, mmol/L                                               1925                 6.9 (1.2)                              3616                              6.4 (1.1)       \<0.0001     7% (5 to 9)      −5% (−8 to −2)     0% (−1 to 1)
  Triglycerides, mmol/L[\*](#nt102){ref-type="table-fn"}                  1925               1.1 (0.9−1.5)                            3616                            1.0 (0.8−1.4)     \<0.0001   21% (19 to 23)    −14% (−17 to −11)    2% (0 to 3)
  Lipoprotein(a), mg/L[\*](#nt102){ref-type="table-fn"}                   1917                115 (39−283)                            3612                             82 (25−199)      \<0.0001   −3% (−5 to −2)      1% (−2 to 4)      0% (−1 to 1)
  **Inflammatory markers**                                                                                                                                                                                                              
  Interleukin 6, ng/L[\*](#nt102){ref-type="table-fn"}                    1658               2.1 (1.4--3.4)                           3060                            1.9 (1.2--2.9)    \<0.0001     5% (4 to 7)       13% (9 to 17)      5% (4 to 6)
  C-reactive protein, mg/L[\*](#nt102){ref-type="table-fn"}               1906               1.7 (0.8--3.5)                           3573                            1.2 (0.6--2.7)    \<0.0001   13% (11 to 14)       6% (3 to 9)       8% (7 to 9)
  **Rheological markers**                                                                                                                                                                                                               
  Hematocrit, %                                                           1925                 44.7 (4.7)                             3616                              44.1 (4.5)      \<0.0001    10% (9 to 12)     −8% (−12 to −5)    0% (−2 to 1)
  Hemoglobin, g/L                                                         1917                148.3 (13.1)                            3599                             145.9 (13.1)     \<0.0001   16% (14 to 18)    −14% (−17 to −11)   1% (−1 to 2)
  ESR, mm/hr[\*](#nt102){ref-type="table-fn"}                             1838              8.0 (4.0--15.0)                           3427                           7.0 (3.0--13.0.)   \<0.0001     3% (1 to 5)      16% (12 to 20)     9% (7 to 10)
  **Hemostatic markers**                                                                                                                                                                                                                
  t-PA antigen, ng/mL[\*](#nt102){ref-type="table-fn"}                    1925              13.9 (9.9--18.8)                          3616                           12.6 (8.8--17.2)   \<0.0001         --          −15% (−18 to −12)    6% (5 to 8)
  D-dimer, ng/mL[\*](#nt102){ref-type="table-fn"}                         1925               115 (60--246)                            3616                            121 (64--241)      0.280     −8% (−10 to −7)          --            7% (6 to 8)
  VWF, IU/dL[\*](#nt102){ref-type="table-fn"}                             1925               107 (81--141)                            3616                            106 (78--136)      0.008       7% (6 to 9)      17% (14 to 21)          --
  **Others**                                                                                                                                                                                                                            
  Serum creatinine (µmol/L)                                               1907                  77 (20)                               3587                               75 (13)        \<0.001      7% (5 to 9)       0% (−4 to 3)       3% (1 to 5)

Abbreviations: ESR, erythrocyte sedimentation rate; IQR, inter-quartile range.

Means (SDs) of log~e~ transformed values in cases and controls were 0.2 (0.5) and 0.0 (0.4) for triglycerides; 4.4 (1.6) and 4.0 (1.7) for lipoprotein (a); 0.8 (0.8) and 0.7 (0.8) for interleukin 6; 0.5 (1.1) and 0.2 (1.1) for C-reactive protein; 2.0 (1.0) and 1.9 (1.0) for erythrocyte sedimentation rate; 2.6 (0.5) and 2.5 (0.5) for t-PA antigen; 4.8 (1.0) and 4.8 (1.0) for D-dimer; and 4.7 (0.4) and 4.6 (0.4) for VWF.

Percentage differences and 95% CIs were calculated per 1 SD higher level or compared to the reference category of variables shown in the left column (adjusted for age, sex and period of recruitment).

Associations with Incident CHD in the Reykjavik Study {#s3b}
-----------------------------------------------------

After adjustment for age, sex and period of recruitment, baseline levels of t-PA antigen were apparently log-linearly related to CHD risk ([**Figure 2**](#pone-0055175-g002){ref-type="fig"}), yielding an OR of 1.25 (1.18, 1.33) per 1 SD higher level ([**Table 2**](#pone-0055175-t002){ref-type="table"}). This OR fell to 1.07 (0.99, 1.14) after further adjustment for several non-lipid and lipid risk factors. VWF was also log-linearly associated with CHD risk (OR = 1.11 \[1.05, 1.18\] minimally adjusted; 1.08 \[1.02, 1.15\] further adjusted). However, there was no evidence of a significant association between baseline levels of D-dimer and CHD risk (OR = 1.01 \[0.95, 1.07\] minimally adjusted; 1.06 \[1.00, 1.13\] further adjusted). In a head-to-head comparison, t-PA antigen, D-dimer and VWF were more weakly associated with incident CHD than several established and emerging markers ([**Figure 3**](#pone-0055175-g003){ref-type="fig"}). ORs did not vary substantially when further adjustment was made for C-reactive protein ([**Table 2**](#pone-0055175-t002){ref-type="table"}). Apart from a possibly weaker association of t-PA antigen in current smokers compared with non-smokers (P = 0.003), ORs for CHD did not vary in clinically relevant subgroups defined by diabetes status, lipids, obesity, or other individual-level characteristics (**[Figure S6](#pone.0055175.s006){ref-type="supplementary-material"}**).

![Associations of baseline t-PA antigen, D-dimer and VWF with coronary heart disease risk (Reykjavik Study).\
Odds ratios (95% CI) for coronary heart disease are shown by fifths of baseline t-PA antigen, D-dimer and VWF, plotted against the geometric mean level in each category on a log-doubling scale. \*Adjusted for age, sex, period of recruitment, smoking status, body mass index, systolic blood pressure, history of diabetes, total cholesterol and log~e~ triglycerides.](pone.0055175.g002){#pone-0055175-g002}

![Head-to-head comparison of associations of various baseline variables with coronary heart disease risk (Reykjavik Study).\
\*Values were log~e~ transformed for analysis. †Adjusted for age, sex, period of recruitment, smoking status, body mass index, systolic blood pressure, history of diabetes, total cholesterol and log~e~ triglycerides.](pone.0055175.g003){#pone-0055175-g003}

10.1371/journal.pone.0055175.t002

###### Association of baseline levels of t-PA antigen, D-dimer and VWF with coronary heart disease in the Reykjavik Study (1925 cases, 3616 controls).
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  Adjustment                                                    Odds ratios for coronary heart disease (95% CI) per 1 SD higher level                      
  ------------------------------------------------------------ ----------------------------------------------------------------------- ------------------- -------------------
  Adjusted for age, sex and period of recruitment                                         1.25 (1.18, 1.33)                             1.01 (0.95, 1.07)   1.11 (1.05, 1.18)
  \+ non-lipid risk factors[\*](#nt104){ref-type="table-fn"}                              1.14 (1.07, 1.22)                             1.04 (0.98, 1.10)   1.08 (1.02, 1.15)
  \+ lipid risk factors[†](#nt105){ref-type="table-fn"}                                   1.07 (0.99, 1.14)                             1.06 (1.00, 1.13)   1.08 (1.02, 1.15)

Smoking status, body mass index, systolic blood pressure and any history of diabetes mellitus at baseline.

Total cholesterol and log~e~ triglycerides.

When analyses were restricted to participants with complete information on C-reactive protein (1906 cases, 3573 controls), the odds ratios (95% CI) per 1 SD higher value of t-PA antigen were 1.26 (1.18, 1.33) when adjusting for age, sex and period of recruitment, 1.15 (1.07, 1.22) when additionally adjusting for non-lipid risk factors, 1.07 (0.99, 1.14) when additionally adjusting for lipid risk factors and 1.04 (0.97, 1.11) when additionally adjusting for C-reactive protein. Corresponding odds ratios were 1.01 (0.95, 1.07), 1.04 (0.98, 1.11), 1.07 (1.00, 1.14) and 1.05 (0.99, 1.12) for D-dimer and 1.12 (1.05, 1.18), 1.09 (1.02, 1.15), 1.09 (1.03, 1.16) and 1.06 (1.00, 1.13) for VWF.

Correction for Long-term within-person Variability {#s3c}
--------------------------------------------------

In up to 371 participants who provided paired measurements at baseline and a mean (SD) of 11.6 (1.3) years later, age- and sex-adjusted RDRs were 0.47 (95% CI 0.38, 0.56) for t-PA antigen, 0.30 (0.22, 0.38) for D-dimer and 0.55 (0.47, 0.63) for VWF (**[Table S3](#pone.0055175.s013){ref-type="supplementary-material"}**). The within-person variability over 11.6 years in the current study was somewhat greater than reported in previous studies with measurements taken 5 or fewer years apart (p≤0.007 for trend with time, **[Figure S7](#pone.0055175.s007){ref-type="supplementary-material"}**). After correction for within-person variability in levels of the exposures, the ORs per 1 SD higher level were 1.15 (1.01, 1.32) for t-PA antigen, 1.11 (0.99, 1.25) for D-dimer 1.10 (1.03, 1.19) for VWF.

Systematic Review and Updated Meta-analyses {#s3d}
-------------------------------------------

Together with the current study, 21 relevant published prospective studies were identified (13 with t-PA antigen, 18 with D-dimer and 15 with VWF measurement) [@pone.0055175-Danesh1]--[@pone.0055175-Wannamethee1], [@pone.0055175-Folsom1]--[@pone.0055175-Lowe4]. Study characteristics and references are provided in [**Table 3**](#pone-0055175-t003){ref-type="table"}. All but one were based in the United States or Europe. Most identified participants in population registers or in occupational settings and reported on incident MI or CHD death outcomes (mean follow-up ranged from about 2.4 to 19.4 years). Measurements generally involved enzymatic immunoassays, performed in plasma (17 studies) or serum (4 studies), thawed after long-term storage at −20°C (4 studies), −40°C (1 study), −70 or −80°C (14 studies) or in liquid nitrogen (2 studies). Reported levels of t-PA antigen and VWF were consistent across studies, while levels of D-dimer varied substantially (ranging from around 10 to over 600 IU/dL). A combined analysis of available data yielded adjusted RRs of 1.13 (1.06, 1.21), 1.23 (1.16, 1.32) and 1.16 (1.10, 1.22) per 1 SD higher baseline levels of t-PA antigen (5494 CHD cases), D-dimer (6799 CHD cases) and VWF (6556 CHD cases), respectively ([**Figure 4**](#pone-0055175-g004){ref-type="fig"}). There was some evidence of heterogeneity in RRs, but little of it was explained by recorded study-level characteristics (**[Figure S9](#pone.0055175.s009){ref-type="supplementary-material"}**). There was some evidence that smaller studies of D-dimer reported more striking findings (Egger's test, *P* = 0.004; **[Figure S10](#pone.0055175.s010){ref-type="supplementary-material"}**), but this trend was not apparent when results from studies with 500 CHD cases or more were compared with those from smaller studies in the pre-specified subgroup analyses (**[Figure S9](#pone.0055175.s009){ref-type="supplementary-material"}**).

![Meta-analyses of reported associations of t-PA antigen, D-dimer and VWF with coronary heart disease risk in prospective population-based studies.\
Study acronyms are explained in the legend of [**Table 3**](#pone-0055175-t003){ref-type="table"}. Summary estimates were calculated using random effects models. \*Degree of adjustment:+minimally adjusted (typically adjusted for age and sex only);++plus adjustment for at least one non-lipid marker;+++plus adjustment for at least one lipid marker;++++plus adjustment for at least one inflammatory marker. Where studies reported relative risks with more than one level of statistical adjustment, the most adjusted estimate was used (least adjusted estimates are reported in **[Figure S8](#pone.0055175.s008){ref-type="supplementary-material"}**).](pone.0055175.g004){#pone-0055175-g004}

10.1371/journal.pone.0055175.t003

###### Characteristics of 21 published prospective studies of t-PA antigen, D-dimer and VWF.
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                                                                                                                                                                                               Blood sample                    Assay manufacturer   Mean level                                                                                                                     
  -------------------------------------------------------------------- ------------ ------------------------ ---------- -------- ------ --------------------------------------- ------------- -------------- -------- ------- -------------------- ------------ ------------- ------------- ---------- ------------------------------------- ------------------------------------- -------------------------------------
  **Current study**                                                                                                                                                                                                                                                                                                                                                                
  Reykjavik                                                              Iceland      Population register     1969--96   33--86    70    19.4[†](#nt109){ref-type="table-fn"}        CHD           Yes        Serum     −20           1925             3616        Biopool       Hyphen        Dako                    13.7                                   198                                   112
  **Previously published**                                                                                                                                                                                                                                                                                                                                                         
  ARIC [@pone.0055175-Folsom1]                                             USA         Household listings     1987--89   45--64    43                     4.3                      CHD, CS         Yes        Plasma    −70           326              692       Diagnostica   Diagnostica                            7.6\|\|                               303\|\|                
  ARIC [@pone.0055175-KucharskaNewton1]                                    USA         Household listings     1987--89   45--64    43                    12.4                    Nonfatal MI       Yes        Plasma    −70           737             13272                                    AmB                                                                                                  NR
  BRHS[\*](#nt108){ref-type="table-fn"} [@pone.0055175-Lowe2]               UK              GP lists          1978--80   40--59   100     18[‡](#nt110){ref-type="table-fn"}         CHD            No        Serum     −20           606              1227        Biopool                                           10.4\|\|                                                      
  BRHS[\*](#nt108){ref-type="table-fn"} [@pone.0055175-Danesh1]             UK              GP lists          1978--80   40--59   100     18[‡](#nt110){ref-type="table-fn"}         CHD            No        Serum     −20           630              1269                       AGEN                                                                        130                  
  BRHS[\*](#nt108){ref-type="table-fn"} [@pone.0055175-Whincup1]            UK              GP lists          1978--80   40--59   100     18[‡](#nt110){ref-type="table-fn"}         CHD            No        Serum     −20           625              1266                                    Dako                                                                                                 113
  BRHS[\*](#nt108){ref-type="table-fn"} [@pone.0055175-Wannamethee1]        UK              GP lists          1998--00   60--79   100                      7                         CHD           Yes        Plasma    −70           198              2809        Biopool       Biopool       Dako                    10.8                                   80                                    137
  BWHHS [@pone.0055175-May1]                                                UK        Population register     1999--01   60--79    0      4.7[†](#nt109){ref-type="table-fn"}    CHD, CS, AP       Yes        Plasma    −80           198              3384        Biopool       Biopool       Dako                   7.9\|\|                               88\|\|                                139\|\|
  Caerphilly [@pone.0055175-Smith1]                                         UK          Electoral rolls       1984--88   49--65   100    13.4[†](#nt109){ref-type="table-fn"}        CHD           Yes        Plasma    −70           316              1665        Biopool                     Dako                  10.9\|\|                                                                     113\|\|
  Caerphilly [@pone.0055175-Smith1]                                         UK          Electoral rolls       1984--88   49--65   100    13.4[†](#nt109){ref-type="table-fn"}        CHD           Yes        Plasma    −70           310              1621                       AGEN                                                                      12\|\|                 
  CHS [@pone.0055175-Cushman1]                                             USA           Medicare lists       1989--90    65+      61                     2.4                        CHD           Yes        Plasma    −70            70               70                      In-house                                                                      NR                   
  EAS [@pone.0055175-Tzoulaki1]                                             UK              GP lists            1988     55--74    53                     17                         CHD           Yes        Plasma    −40           248              1177        Biopool        AGEN         Dako     7.0[†](#nt109){ref-type="table-fn"}   80[†](#nt109){ref-type="table-fn"}    105[†](#nt109){ref-type="table-fn"}
  Fletcher [@pone.0055175-Woodward1]                                        NZ       Occupational/electoral   1992--94   19--86    72     5.5[†](#nt109){ref-type="table-fn"}        CHD            No        Plasma    −70           194              399         Hyphen                      Dako                     4.7                                                                         127
  Fletcher [@pone.0055175-Woodward1]                                        NZ       Occupational/electoral   1992--94   19--86    72     5.5[†](#nt109){ref-type="table-fn"}        CHD            No        Plasma    −70           190              387                       R&D Sys                                                                      253                  
  Glostrup [@pone.0055175-Gram1]                                         Denmark      Population register     1976--84   30--60    73    7--15[§](#nt111){ref-type="table-fn"}       CHD           Yes        Serum     −20           133              258         Biopool                                              7.8                                                        
  MESA [@pone.0055175-Folsom2]                                             USA         General population     2000--02   45--84    47     4.6[†](#nt109){ref-type="table-fn"}        CHD           Yes        Plasma    −70           207              6184                      DStago                                                       205[†](#nt109){ref-type="table-fn"}  
  NPHS-I [@pone.0055175-Meade1]                                             UK       Occupational register    1978--84   40--64   100                    10.1                        CHD           Yes        Serum    −196            84              933                                   In-house                                                                                               77%
  NSHDS [@pone.0055175-Wennberg1]                                         Sweden       General population     1985--99   25--74    79                     14                         CHD           Yes        Plasma    −80           467              893         Biopool                                              8.0                                                        
  NSHDS [@pone.0055175-Wennberg1]                                         Sweden       General population     1985--99   25--74    79                     14                         CHD           Yes        Plasma    −80           458              882                       Hyphen                                                                       174                  
  NSHDS [@pone.0055175-Wennberg1]                                         Sweden       General population     1985--99   25--74    79                     14                         CHD           Yes        Plasma    −80           469              895                                     Dako                                                                                                 141
  PHS [@pone.0055175-Ridker1]                                              USA       Occupational register    1982--84   40--84   100                      5                         CHD            No        Plasma    −80           231              231         Biopool                                              9.2                                                        
  PHS [@pone.0055175-Ridker2]                                              USA       Occupational register    1982--84   40--84   100                      5                         CHD            No        Plasma    −80           296              296                       Biopool                                                                      49                   
  PRIME [@pone.0055175-Empana1]                                         France/NI      General population     1991--93   50−59    100      5[‡](#nt110){ref-type="table-fn"}         CHD           Yes        Plasma   --196          162              324                       DStago       DStago                                          255[†](#nt109){ref-type="table-fn"}   114[†](#nt109){ref-type="table-fn"}
  PROSPER [@pone.0055175-Rumley1]                                       SCO/IRE/NL   Primary care screening     1998     70--82    48                     3.2                        CHD           Yes        Plasma    −80           372              2750        Hyphen                                              11.0                                                        
  PROSPER [@pone.0055175-Rumley1]                                       SCO/IRE/NL   Primary care screening     1998     70--82    48                     3.2                        CHD           Yes        Plasma    −80           373              2806                      Hyphen                                                                       270                  
  PROSPER [@pone.0055175-Rumley1]                                       SCO/IRE/NL   Primary care screening     1998     70--82    48                     3.2                        CHD           Yes        Plasma    −80           369              2739                                    Dako                                                                                                 139
  Rotterdam [@pone.0055175-vanLoon1]                                        NL        Population register     1989--93    55+     39.8                    6.4                      CHD, CS         Yes        Plasma    −80           473              5328                                    Dako                                                                                                 130
  Speedwell [@pone.0055175-Lowe3]                                           UK              GP list           1982--85   49--67   100                    6.25                        CHD            No        Plasma    −20           165              1554                      Biopool                                                                    41\|\|                 
  Three-City [@pone.0055175-Carcaillon1]                                  France        Electoral rolls       1999--01    65+     39.5     4[‡](#nt110){ref-type="table-fn"}     CHD, CS, AP       Yes        Plasma    −80           199              1053                      DStago       DStago                                                        576\|\|                              130%\|\|
  WHI [@pone.0055175-Pradhan1]                                             USA        Population register     1993--98   50--79    0                      2.9                        CHD           Yes        Plasma    −70           280              280           AmD                                7.4[†](#nt109){ref-type="table-fn"}                                        
  WHI [@pone.0055175-Kim1]                                                 USA        Population register     1993--98   50--79    0       4[‡](#nt110){ref-type="table-fn"}         CHD           Yes        Plasma    −70           359              820                         AmD         AmD                                            300[†](#nt109){ref-type="table-fn"}   93%[†](#nt109){ref-type="table-fn"}
  WOSCOPS [@pone.0055175-Lowe4]                                             UK       Heart screening clinic   1989--91   45--64   100      6[‡](#nt110){ref-type="table-fn"}       CHD, CS         Yes        Plasma    −70           485              934                       Biopool                                                                      60                   

**Abbreviations:** **AmB**, American Bioproducts; **AmD**, American Diagnostica; **AP**, angina pectoris; **ARIC**, Atherosclerosis Risk in Communities Study; **BRHS**, British Regional Heart Study; **BWHHS**, British Women's Heart and Health Study; **Caerphilly**, Caerphilly Prospective Study; **CHD**, coronary heart disease endpoint (composed of nonfatal myocardial infarction and coronary death); **CHS**, Cardiovascular Health Study; **CS**, coronary surgery; **DStago**, Diagnostica Stago; **EAS**, Edinburgh Artery Study; **ELISA**, enzyme-linked immunosorbent assay; **FHS**, Framingham Heart Study; **Fletcher**, Fletcher Challenge Study; **Glostrup**, Glostrup population studies; **IRE**, Ireland; **IT**, immunoturbidometry; **MESA**, Multi-Ethnic Study of Atherosclerosis; **MI**, myocardial infarction; **NPHS-I**, Northwick Park Heart Study I; **NSHDS**, Northern Sweden Health and Diseases Study cohort; **PHS**, Physicians' Health Study; **PRIME**, Prospective Epidemiological Study of Myocardial Infarction; **PROSPER**, Prospective Study of Pravastatin in the Elderly at Risk; **NI**, Northern Ireland; **NL**, Netherlands; **NR**, not reported; **NZ**, New Zealand; **R&D Sys**, R&S Systems; **RE**, rocket electrophoresis; **Rotterdam**, Rotterdam Study; **SCO**, Scotland; **Speedwell**, Speedwell Study; **Three-City**, Three-City cohort study; **WHI**, Women's Health Initiative; **WOSCOPS**, The West of Scotland Coronary Prevention Study.

Reports with two different study baselines and non-overlapping follow-up periods are available.

Median.

Maximum.
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Discussion {#s4}
==========

In the Reykjavik Study, the largest population-based study of t-PA antigen, D-dimer and VWF to date, we observed at most weak associations of these markers with the risk of CHD, when adjusting for a panel of conventional cardiovascular risk factors. However, in the context of the updated meta-analyses that involved up to ten times as much data as previously reported [@pone.0055175-Danesh1]--[@pone.0055175-Lowe2], higher levels of t-PA antigen, D-dimer and VWF at baseline were compatible with modest increases in risk. As suggested by previous reports, while t-PA antigen was positive associated with various risk factors, including male sex, blood pressure, body mass index, triglycerides, inflammatory markers and rheological markers [@pone.0055175-Lowe2], [@pone.0055175-Folsom1], D-dimer was inversely associated with these risk factors and also inversely associated with t-PA antigen levels [@pone.0055175-Danesh1]. This inverse association could arise because t-PA antigen levels largely reflect circulating t-PA/PAI-1 complexes, and higher PAI-1 levels reduce endogenous fibrinolysis and hence D-dimer levels. Finally, baseline VWF levels were largely independent from other cardiovascular risk factors (with weak correlations with C-reactive protein and smoking status).

Although the combined estimates from the current study and previous reports were compatible with modest increases in risk, the relationships of these three markers with CHD risk remain uncertain, as evidenced by: the comparatively wide confidence intervals around the pooled RRs; a tendency for more extreme associations in smaller studies suggesting the likelihood of some exaggeration in the overall estimates; and most importantly, potential residual confounding, as the meta-analyses pooled associations adjusted for baseline levels of confounders only [@pone.0055175-Clarke1]. The associations of t-PA antigen, D-dimer and VWF with first-ever MI or CHD death may therefore be more modest than previously reported, but the current findings do not, of course, preclude stronger associations in high-risk populations [@pone.0055175-McCann1], [@pone.0055175-Spiel1] or with different vascular outcomes [@pone.0055175-Eichinger1], [@pone.0055175-Lowe5].

To help clarify whether activated coagulation and fibrinolysis play an etiological role in the development of CHD, future investigations should involve complementary approaches to help judge causality, such as study of potential interrelations with ABO(H) blood groups [@pone.0055175-Smith2], [@pone.0055175-Smith3]; investigation of more direct markers such as t-PA activity or VWF multimer patterns [@pone.0055175-Vischer1]; and mendelian randomization studies using genetic variants as potentially unconfounded proxies for circulating levels of these markers [@pone.0055175-vanSchie1]--[@pone.0055175-Huang1]. In particular, VWF levels may be a plausible mediator of the association of non-O blood groups with CHD and other thrombotic disorders [@pone.0055175-Wu1].

Furthermore, the within-person variability of these hemostatic markers is greater than previously reported and highlights the importance of correction for variability in long-term prospective studies and the potential advantages of identifying genetic variants as proxies for these error-prone biomarkers [@pone.0055175-Rudnicka1]. While literature-based data indicate a declining self-correlation over time, suggesting that single "snapshot" baseline measurements do not perfectly capture long-term "usual" levels, the magnitude of this remains to be determined in detail. Information on the repeatability of such measurements over time is currently available on only around 2000 individuals in aggregate and is based predominantly on summary findings from published reports and not individual data.

The strengths and limitations of the current report merit careful consideration. Our new data from the Reykjavik Study involve more than three times as many cases of first-ever CHD as in the previous largest reports [@pone.0055175-Danesh1]--[@pone.0055175-Lowe2]. Participants were identified in population registers, had high response and follow-up rates, used robust methods to ascertain CHD outcomes and minimized potential biases by exclusion of participants with prevalent cardiovascular disease. Concomitant measurements of several factors enabled direct comparisons with different markers and allowed adjustment for a range of possible confounders, although we acknowledge that data on some biological factors was lacking [@pone.0055175-Arnett1], [@pone.0055175-Wennberg2]. Repeat measurements several years apart enabled assessment of and allowance for long-term within-person variability, but no data were available to account for short-term variability, such as diurnal or seasonal fluctuations [@pone.0055175-Rudnicka1], [@pone.0055175-Ghebre1]. Although the current study involved blood storage at −20°C for a median time of 29 years (range 4 to 33 years), the distributions of t-PA antigen, D-dimer and VWF were broadly in keeping with those reported previously, as exemplified by the WHO-MONICA optional Haemostasis Study of 11 centers across Europe that also included Iceland [@pone.0055175-Yarnell1]. Furthermore, the generally similar correlations at baseline with cardiovascular risk factors in this and other studies, plus the lack of any significant heterogeneity in associations with CHD risk across studies with different lengths of follow-up or sample storage conditions in the updated meta-analyses, argues against sample degradation as an explanation for our findings. Finally, although the updated meta-analyses included in our report represent the most comprehensive synthesis of the available data to date, they rely on published reports only. Access to individual participant data would permit more consistent comparisons across studies (such as in the outcomes, covariates and subgroups considered).

Conclusions {#s4a}
-----------

Concentrations of t-PA antigen, D-dimer and VWF may be more modestly associated with first-ever CHD events than previously reported. More detailed analysis is required to clarify whether these markers are causal risk factors or simply correlates of coronary heart disease.
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**Cross-sectional correlates of baseline levels of VWF.**
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**Explorative analysis of effect modification of the associations of baseline levels of t-PA antigen, D-dimer and VWF with coronary heart disease risk in the Reykjavik study.** Continuous variables were categorized based on tertile cut-offs in controls. All models are adjusted for age, sex, period of recruitment, smoking status, body mass index, systolic blood pressure, history of diabetes at baseline, total cholesterol, and loge triglycerides. \*P values were calculated using likelihood ratio tests comparing models with and without interaction terms.
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**Estimated within-person variability of t-PA antigen, D-dimer and VWF by time since baseline measurement in the published literature.** Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; BRHS, British Regional Heart Study; EAS, Edinburgh Artery Study; Fletcher, Fletcher Challenge Study; Reykjavik, Reykjavik Study. Each point represents unadjusted study- and time-specific estimates of within-person variability (eg, reported correlation coefficients or regression dilution ratios) in paired samples taken some time apart. Grey boxes represent unadjusted estimates. The relative sizes of the boxes are proportional to the inverse of the standard errors.
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**Meta-analyses of reported associations of t-PA antigen, D-dimer and VWF with coronary heart disease risk in population-based prospective studies. Where studies reported more than one odds ratio, the least adjusted estimate was used.** Study acronyms are explained in the legend of [Table 3](#pone-0055175-t003){ref-type="table"}. Summary estimates were calculated using random effects models. \*Degree of adjustment:+minimally adjusted (typically adjusted for age and sex only);++plus adjustment for at least one non-lipid marker;+++plus adjustment for at least one lipid marker;++++plus adjustment for at least one inflammatory marker. Where studies reported relative risks with more than one level of statistical adjustment, the least adjusted estimate was used (most adjusted estimates are reported in [Figure 4](#pone-0055175-g004){ref-type="fig"}).
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**Investigation of sources of possible heterogeneity in reported associations of t-PA antigen, D-dimer and VWF with coronary heart disease risk, according to various study-level characteristics.** Summary estimates were calculated using random effects models. \*P values are from meta-regression for differences in odds ratios across studies in different groups.
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**Funnel plots of reported associations of t-PA antigen, D-dimer and VWF with coronary heart disease risk.** The dotted lines show 95% confidence intervals around the overall summary estimate calculated using fixed effect models. Egger's test for regression asymmetry: t-PA antigen, P = 0.086; D-dimer, P = 0.004; VWF, P = 0.290.
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**Comparison of baseline characteristics of coronary heart disease cases, randomly selected controls and the overall Reykjavik cohort.** \*Controls were matched to coronary heart disease cases by sex and age (in five-year age bands) and therefore differ from the remainder of the Reykjavik cohort.
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**PRISMA 2009 Checklist.** From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097. For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).
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**Within-person variability of t-PA antigen, D-dimer and VWF plus other measured markers (mean time between repeated measurements, 11.6 years).**
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**Systematic review and updated meta-analysis.**
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